Clinical Trials Sponsored by Vallon Pharmaceuticals, Inc.

Total 5083 results

Alcon LenSx, Inc.

Completed

Creating LASIK Flaps With the LenSx Femtosecond Laser

Myopia | Hyperopia

Hungary
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Amyloidosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
BioMed Valley Discoveries, Inc

Completed

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Advanced Solid Tumors

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
BioMed Valley Discoveries, Inc

Terminated

[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

Diabetic Foot Infection

United States
Ligand Pharmaceuticals
CyDex Pharmaceuticals, Inc.

Withdrawn

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Contrast-induced Nephropathy
Paratek Pharmaceuticals Inc
Novartis Pharmaceuticals

Terminated

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (CSSI)

Skin Diseases, Infectious

United States
ChemGenex Pharmaceuticals

Completed

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Hematologic Tumors

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Pneumonia | Ventilators, Mechanical
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Nucorion Pharmaceuticals, Inc.
Ligand Pharmaceuticals

Completed

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Chronic Hepatitis B

United States
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Hepatitis C, Chronic

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Liver Transplantation | Hepatitis | Carcinoma, Hepatocellular | Cholestasis

United States, Germany
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

Suspended

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease (GREEN MEMORY)

Alzheimer Disease

Hong Kong, China, United States, Canada, Poland, France, Australia, Czechia, Netherlands, Taiwan
BioMed Valley Discoveries, Inc

Recruiting

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Gastrointestinal Cancer | Tumor, Solid

United States
BioMed Valley Discoveries, Inc

Terminated

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States
BioMed Valley Discoveries, Inc

Completed

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Solid Tumor Malignancies

United States
BioMed Valley Discoveries, Inc

Completed

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

Healthy
BioMed Valley Discoveries, Inc

Terminated

[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint (PJI)

Prosthetic Joint Infections

United States
BioMed Valley Discoveries, Inc

Terminated

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Solid Tumor Malignancies

United States
BioMed Valley Discoveries, Inc

Completed

Biodistribution and Dosimetry Evaluation of [124I]FIAU

Prosthesis Related Infections

United States
Ionis Pharmaceuticals, Inc.

Not yet recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Shuttle Pharmaceuticals, Inc.

Not yet recruiting

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Glioblastoma, IDH-wildtype

United States
Stamford Pharmaceuticals, Inc.

Recruiting

To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Basal Cell Carcinoma

United States
Gunkang Pharmaceuticals, Inc

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for Colonoscopy (GNS-212-E)

Colonoscopy | Bowel Preparation

Korea, Republic of
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Germany, Colombia, Japan, China, France, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
Pacira Pharmaceuticals, Inc

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Postoperative Pain

United States
NeuroBo Pharmaceuticals Inc.

Recruiting

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Obesity

United States
Rhythm Pharmaceuticals, Inc.

Recruiting

A Study of RM-718 in Healthy Subjects and in Patients With HO

Hypothalamic Obesity

United States
Lipella Pharmaceuticals, Inc.

Not yet recruiting

Evaluating LP-10 in Subjects With OLP

Oral Lichen Planus
Rocket Pharmaceuticals Inc.

Recruiting

Danon Disease Natural History Study

Danon Disease

United States, Germany

Clinical Trials Sponsored by Vallon Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations